This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon: Provenge Sales $2.8 Million

Updated with stock price, conference call comments.

SEATTLE ( TheStreet) -- Dendreon (DNDN) reported second quarter Provenge sales of $2.8 million, the first financial measure of the prostate cancer therapy's commercial launch since it gained U.S. approval in late April.

On average, analysts were expecting Provenge revenue of about $4 million in the quarter, so the prostate cancer therapy's performance fell short of consensus. The black-or-white, win-or-lose nature of Wall Street earnings reports all but requires such a definitive statement.

Yet the Provenge launch isn't typical since Dendreon can't make enough to satisfy patient demand. The company long ago told investors that limited manufacturing capacity would only allow about 2,000 patients to be treated in the first 12 months of the launch.

As a signal that demand for Provenge is strong, the company said sales totaled $5.2 million in July and doctors wrote 500 Provenge prescriptions in the first three months of the drug's launch. Five hundred patients have not yet been treated with Provenge, but the number represents a proxy for future demand and revenue.

The Provenge outlook helped boost Dendreon shares 4% to $35.30 in Tuesday's after-market trading session. Prior to the earnings release, Dendreon closed flat at $33.83.

The U.S. Food and Drug Administration approved Provenge on April 29. Provenge is the first cancer drug approved that works by activating a patient's own immune system to fight the disease. Under the FDA approval, Dendreon markets Provenge as a treatment for men with advanced prostate cancer that has grown resistant to standard hormone treatment.

Despite the supply constraints, investors have been watching Provenge's commercial launch very closely to see how insurance companies react to the drug's $93,000 price tag. Wall Street is also judging Dendreon's ability to manufacture and deliver on time a cancer drug that must be customized for each patient.

On Tuesday's call, Dendreon said 14 of the 15 regional Medicare carriers have communicated in some way their intent to reimburse Provenge. Private insurance carriers are also providing reimbursement. Dendreon shares took a hit recently when the U.S. government agency that oversees the Medicare program announced plans to initiates a national coverage assessment for Provenge.

Dendreon also reiterated that expansion of the three Provenge manufacturing facilities are on track to bring supply up to full capacity in the middle of 2011.

Dendreon launched Provenge in May so the company reported less than a quarter's worth of sales Tuesday. Expectations, however, only ramp up from here. At present, consensus Provenge sales are $23 million in the current quarter and $44 million in the fourth quarter. Next year, Wall Street is looking for Provenge sales topping $360 million.

Also Tuesday, Dendreon reported a net loss of $142.6 million, or $1.04 a share, below with Wall Street's consensus forecast.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DNDN $0.06 -6.02%
AAPL $94.99 -0.02%
FB $99.54 -0.21%
GOOG $678.11 -0.68%
TSLA $148.25 0.18%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs